ArQule begins dosing of ARQ 092 in Phase I/II trial for overgrowth diseases
US-based biopharmaceutical firm ArQule has begun dosing patients with ARQ 092 in a Phase I/II clinical trial to treat patients with rare overgrowth diseases.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Clinical Trials | Pharmaceuticals